Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanctura Accounts For 7.6% Of New Overactive Bladder Scripts By Urologists

This article was originally published in The Pink Sheet Daily

Executive Summary

Indevus/Pliva's overactive bladder product has gained 3% of new scripts overall since its August launch. Indevus plans to begin Phase III trials of Sanctura XR in mid-2005.

You may also be interested in...



No Pauses For Pagoclone: Indevus Moving To Phase III For Stuttering

The anxiolytic would be the first drug indicated for the condition.

No Pauses For Pagoclone: Indevus Moving To Phase III For Stuttering

The anxiolytic would be the first drug indicated for the condition.

Sanctura Growth Pushed By Urinary Incontinence Awareness, Pliva Says

Pliva says the recent addition of three new products to the urinary incontinence market is "positive" because of the increase in awareness of the condition. Sanctura has "almost 8%" of market share among urologists, a figure the company hopes will "trickle down" to general practitioners, Pliva says.

Related Content

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel